<DOC>
	<DOCNO>NCT03057444</DOCNO>
	<brief_summary>The aim study investigate , resistant starch type III increase butyrate-producing bacteria gut ( pre- ) diabetic subject . Diabetic blood parameter also interest .</brief_summary>
	<brief_title>Resistant Starch , Gut Bacteria Diabetes</brief_title>
	<detailed_description>Other study show diabetic less butyrate-producing bacteria specie gut compare non-diabetes patient diabetes patient take metformin . Moreover , study demonstrate resistant starch increase butyrate-producing bacteria specie . Furthermore , study show butyrate effect blood glucose insulin homeostasis . The aim study investigate , resistant starch typ III increase butyrate-producing bacteria gut ( pre- ) diabetic subject , The effect blood glucose , insulin HbA1c investigate well . Patients include study typ 2 diabetic lifestyle intervention , insulin antidiabetic medication ( sulfonylureas , glinides , SGLT2-inhibitors , glitazone ) pre-diabetics . They get 2x 5g per day food supplement SymbioIntest ( resistant starch type III ) 8 week . Study examination intervention , 4 week 8 week . Stool sample collect intervention 14 day consecutively end intervention .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>Male female adult person ( ≥ 18 year ) Type 2 diabetes mellitus discontinue lifestyle intervention insulin therapy oral antidiabetic therapy ( sulphonylureas , glinides , SGLT2 ( sodium/glucose cotransporter 2 ) inhibitor , glitazone ) prediabetic metabolism It foreseeable therapy metformin αglucosidase inhibitor DPP4 ( Dipeptidyl peptidase4 ) inhibitor initiate period study ( 8 week ) willingness systematically change diet lifestyle habit study Adequate understanding German language sufficient psychological condition understand information instruction associate study complete questionnaire assessment scale Signed informed consent Treatment Type II diabetes mellitus metformin αglucosidase inhibitor DPP4 inhibitor Diminished diabetic metabolic position medical necessity convert therapy foreseeable future ( HbA1c ≥ 7 % fast glucose ≥ 152 mg / dl ) Participation another clinical trial ( currently within last 30 day ) Incompatibility ingredients investigational medicinal product Pregnancy lactation Inability take test preparation orally change dietary habit habit within last 30 day Antibiotics intake currently within last 30 day Drug abuse last six month start study ongoing . Alcohol abuse define average daily 20 g alcohol woman 30 g alcohol men , base last six month A state health ( include abnormal laboratory value ) , discretion investigator , allow study participation , evaluation study parameter use investigational medicinal product Accommodation clinic similar facility , administrative judicial order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>resistant starch type III</keyword>
	<keyword>butyrate-producing gut bacteria</keyword>
	<keyword>diabetes mellitus type 2</keyword>
	<keyword>prediabetes</keyword>
</DOC>